JPM26: Regeneron will not overpay in M&A deals amid lead asset patent expiries [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
its internal R&D capacity to develop next-generation assets and expand into new indications. Speaking at the J.P. Morgan Healthcare conference in San Francisco, held from 12 to 15 January, Regeneron CEO Leonard Schleifer said that the company expects to invest $6bn in R&D in 2026, highlighting its strategy to prioritise internal research capabilities. While industry conversations have largely centred around acquisition to combat looming patent cliffs for many companies, Schleifer said large M&A deals often result in “value destruction.” He said that companies can often become “overly reliant” on external sources and are “in most cases, dramatically overpaying.” Despite the volume of deals being down in 2025, average value was up , suggesting that there is currently a premium in M&A pricing. Regeneron will be looking to continue the transition of its Eylea (aflibercept) patient base to the high dose version of the drug, branded Eylea HD, amid an emergence of biosimilars in the
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk Foundation pours $850m into European life sciences economy [Yahoo! Finance]Yahoo! Finance
- ASML Soars Above $500 Billion Value on TSMC's Upbeat Outlook [Yahoo! Finance]Yahoo! Finance
- JPM26: Novo Nordisk reshapes its strategy under new CEO [Yahoo! Finance]Yahoo! Finance
- Eli Lilly: Sell It And Buy Novo Nordisk Instead [Seeking Alpha]Seeking Alpha
- Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website